OBJECTIVE:To observe the efficacy and tolerability of
docetaxel in
treatment of advanced
Breast Cancer', 1, 1614959)"; href="/tags/breast-cancer/">breast cancer and NSCLC.METHODS:Through multicenter prospective study to achieve the objective stated above.RESULTS:Among 29 breast cancer patients,there are 4 CR,12 PR,7 NC and 6 PD after 2～9 cycles of docetaxel treatment in a dose of 75 mg/m2 every 3 weeks,with a
total response rate of 55.2%.Among 32 NSCLC patients,there are 7PR,8 NC,17 PD with a total response rate of 21.9%.The ADRs were mainly stomatitis,diarrhea,fatigue,alopecia,skin reactions,myalgia,and rathralgia.Different grade of hypersensitivity was observed in 4 patients,and three of them stopped treatment.9 patients developed fluid retention without discontinuation of treatment.Most of patients developed leucocytopenia but only few developed anemia and thrombocytopenia.One died of cardiovascular failure after one cycle of treatment.CONCLUSION:In treatment of breast cancer and NSCLC docetaxel in a tolerable dosage of 75 mg/m2 has a better efficacy.
More abstracts about the CLINICAL VALIDATION OF DOCETAXEL IN TREATMENT OF ADVANCED BREAST CANCER AND NSCLC